AstraZeneca's Rezield Hits Another Regulatory Wall
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's request for another clinical trial before approving MedImmune's Rezield for prevention of respiratory syncytial virus could reflect an advisory committee's recommendations that the company show some advantage over its currently approved RSV agent, Synagis, particularly in sicker children